Supplementary Table S2 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses

Supplementary Table S2 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses

<p>Supplemental Table S2 - Differential expression analysis of genes in leukemic or immune cells treated with sEV</p>

Guardat en:

Dades bibliogràfiques
Autor principal:	Ernesto Gargiulo (15134961) (author)
Altres autors:	Elodie Viry (15134964) (author), Pablo Elías Morande (15134967) (author), Anne Largeot (15134970) (author), Susanne Gonder (15134973) (author), Feng Xian (15134976) (author), Nikolaos Ioannou (15134979) (author), Mohaned Benzarti (15134982) (author), Felix Bruno Kleine Borgmann (15134985) (author), Michel Mittelbronn (15134988) (author), Gunnar Dittmar (15134991) (author), Petr V. Nazarov (15134994) (author), Johannes Meiser (15134997) (author), Basile Stamatopoulos (15135000) (author), Alan G. Ramsay (15021857) (author), Etienne Moussay (15135003) (author), Jérôme Paggetti (15135006) (author)
Publicat:	2025
Matèries:	Cancer Tumor Biology Immuno-oncology Methods and Technology Hematological Cancers Leukemias Lymphomas Immunology T cell exhaustion Tumor resistance to immune response Preclinical Models Animal models of cancer Tumor Microenvironment Immune cells and the microenvironment
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars

Figure 1 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
per: Ernesto Gargiulo (15134961)
Publicat: (2025)

Figure 2 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
per: Ernesto Gargiulo (15134961)
Publicat: (2025)

Figure 3 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
per: Ernesto Gargiulo (15134961)
Publicat: (2025)

Figure 4 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
per: Ernesto Gargiulo (15134961)
Publicat: (2025)

Figure 5 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
per: Ernesto Gargiulo (15134961)
Publicat: (2025)

Figure 6 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
per: Ernesto Gargiulo (15134961)
Publicat: (2025)

Figure 7 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
per: Ernesto Gargiulo (15134961)
Publicat: (2025)

Supplementary Table S1 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
per: Ernesto Gargiulo (15134961)
Publicat: (2025)

Supplementary Table S3 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
per: Ernesto Gargiulo (15134961)
Publicat: (2025)

Supplementary Table S4 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
per: Ernesto Gargiulo (15134961)
Publicat: (2025)

Table S1 from HDACi-dependent Microenvironmental Normalization Overcomes Tumor Burden–induced T-cell Exhaustion
per: Andrew Nguyen (17142197)
Publicat: (2025)

Supplementary Figure S1 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
per: Shih-Shih Chen (15314296)
Publicat: (2025)

Supplementary Figure S2 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
per: Shih-Shih Chen (15314296)
Publicat: (2025)

Supplementary Figure S3 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
per: Shih-Shih Chen (15314296)
Publicat: (2025)

Supplementary Figure S4 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
per: Shih-Shih Chen (15314296)
Publicat: (2025)

Supplementary Figure S5 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
per: Shih-Shih Chen (15314296)
Publicat: (2025)

Supplementary Figure S6 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
per: Shih-Shih Chen (15314296)
Publicat: (2025)

Supplementary Table S1 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
per: Shih-Shih Chen (15314296)
Publicat: (2025)

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses
per: Yu Chen (1234761)
Publicat: (2025)

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses
per: Yu Chen (1234761)
Publicat: (2025)

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses
per: Yu Chen (1234761)
Publicat: (2025)

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses
per: Yu Chen (1234761)
Publicat: (2025)

Suppl video 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
per: Andrew O. Yam (15293045)
Publicat: (2025)

Suppl video 2 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
per: Andrew O. Yam (15293045)
Publicat: (2025)

Suppl video 3 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
per: Andrew O. Yam (15293045)
Publicat: (2025)

Suppl video 4 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
per: Andrew O. Yam (15293045)
Publicat: (2025)

Supplementary Table 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
per: Andrew O. Yam (15293045)
Publicat: (2025)

Supplementary Table S1 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
per: Erika Y. Faraoni (14844897)
Publicat: (2025)

Supplementary Table S3 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
per: Erika Y. Faraoni (14844897)
Publicat: (2025)

Supplementary Table S4 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
per: Erika Y. Faraoni (14844897)
Publicat: (2025)

Table S1 from Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2<sup>+</sup> Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma
per: Fanfan Fan (16799646)
Publicat: (2025)

Table S2 from Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2<sup>+</sup> Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma
per: Fanfan Fan (16799646)
Publicat: (2025)

Table S3 from Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2<sup>+</sup> Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma
per: Fanfan Fan (16799646)
Publicat: (2025)

Table S4 from Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2<sup>+</sup> Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma
per: Fanfan Fan (16799646)
Publicat: (2025)

Table S5 from Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2<sup>+</sup> Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma
per: Fanfan Fan (16799646)
Publicat: (2025)

Table S6 from Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2<sup>+</sup> Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma
per: Fanfan Fan (16799646)
Publicat: (2025)

Table S7 from Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2<sup>+</sup> Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma
per: Fanfan Fan (16799646)
Publicat: (2025)

Supplementary Data from PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING–Type I Interferon Signaling in Glioblastoma
per: Isha Mondal (16721699)
Publicat: (2025)

Figure S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
per: Dahihm Kim (16546203)
Publicat: (2025)

Figure S2 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
per: Dahihm Kim (16546203)
Publicat: (2025)

Cannot write session to /tmp/vufind_sessions/sess_eobcqq57et4qqr7es8i1ft2bbt